Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium
The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due t...
Saved in:
Published in | Journal of pharmaceutical sciences Vol. 108; no. 2; pp. 832 - 841 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.02.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples. |
---|---|
AbstractList | The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples. The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples.The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples. |
Author | Ogawa, Taiichiro Kumagai, Takashi Oda, Atsushi Torisu, Tetsuo Okabe, Shinji Takegami, Kazuhiro Nishimura, Hirotaka Murase, Hiroaki Mori, Naoki Akimaru, Michiko Kiyoshi, Masato Saitoh, Satoshi Itakura, Yukari Saito, Shuntaro Shibata, Hiroko Hirokawa, Mai Ishii-Watabe, Akiko Maruno, Takahiro Iwura, Takafumi Harazono, Akira Kikitsu, Aya Takeuchi, Momoko Yasukawa, Hidehito Asano, Yuuka Suetomo, Hiroyuki Ojima, Takuma Ikemoto, Keisuke Uchiyama, Susumu |
Author_xml | – sequence: 1 givenname: Masato surname: Kiyoshi fullname: Kiyoshi, Masato organization: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan – sequence: 2 givenname: Hiroko surname: Shibata fullname: Shibata, Hiroko email: h-shibata@nihs.go.jp organization: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan – sequence: 3 givenname: Akira surname: Harazono fullname: Harazono, Akira organization: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan – sequence: 4 givenname: Tetsuo surname: Torisu fullname: Torisu, Tetsuo organization: Vaccine Operations, Global Vaccine Business Unit, Takeda Pharmaceutical Company Limited, 4720 Takeda, Mitsui, Hikari, Yamaguchi 743-0011, Japan – sequence: 5 givenname: Takahiro surname: Maruno fullname: Maruno, Takahiro organization: U-Medico Inc., 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan – sequence: 6 givenname: Michiko surname: Akimaru fullname: Akimaru, Michiko organization: Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan – sequence: 7 givenname: Yuuka surname: Asano fullname: Asano, Yuuka organization: Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan – sequence: 8 givenname: Mai surname: Hirokawa fullname: Hirokawa, Mai organization: Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan – sequence: 9 givenname: Keisuke surname: Ikemoto fullname: Ikemoto, Keisuke organization: Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan – sequence: 10 givenname: Yukari surname: Itakura fullname: Itakura, Yukari organization: Biologics and New Modalities Development, Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 4720 Takeda, Mitsui, Hikari, Yamaguchi 743-0011, Japan – sequence: 11 givenname: Takafumi surname: Iwura fullname: Iwura, Takafumi organization: Bio Process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd., 100-1, Hagiwara-machi, Takasaki, Gunma 370-0013, Japan – sequence: 12 givenname: Aya surname: Kikitsu fullname: Kikitsu, Aya organization: Pharmaceutical Research Laboratories, Nippon Kayaku Co., Ltd., 3-31-12, Shimo, Kita-ku, Tokyo 115-0042, Japan – sequence: 13 givenname: Takashi surname: Kumagai fullname: Kumagai, Takashi organization: Pharmaceutical Science and Technology Labs, Pharmaceutical Technology, Astellas Pharma Inc., 2-5-3 Tokodai, Tsukuba, Ibaraki 300-2698, Japan – sequence: 14 givenname: Naoki surname: Mori fullname: Mori, Naoki organization: Supply Chain Management Division, Pharmaceutical Research Department, Production Technology, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8505, Japan – sequence: 15 givenname: Hiroaki surname: Murase fullname: Murase, Hiroaki organization: Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan – sequence: 16 givenname: Hirotaka surname: Nishimura fullname: Nishimura, Hirotaka organization: Pharmaceutical Laboratory, Mochida Pharmaceutical Co., Ltd., 342 Gensuke, Fujieda, Shizuoka 426-8640, Japan – sequence: 17 givenname: Atsushi surname: Oda fullname: Oda, Atsushi organization: CMC Regulatory and Analytical R&D, Ono Pharmaceutical Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan – sequence: 18 givenname: Taiichiro surname: Ogawa fullname: Ogawa, Taiichiro organization: CMC Analysis Laboratory, Toray Research Center, Inc., 9-1, Oe-cho, Minato-ku, Nagoya, Aichi 455-8502, Japan – sequence: 19 givenname: Takuma surname: Ojima fullname: Ojima, Takuma organization: Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan – sequence: 20 givenname: Shinji surname: Okabe fullname: Okabe, Shinji organization: Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan – sequence: 21 givenname: Shuntaro surname: Saito fullname: Saito, Shuntaro organization: Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka, Kanagawa 254-0014, Japan – sequence: 22 givenname: Satoshi surname: Saitoh fullname: Saitoh, Satoshi organization: Pharmaceutical Technology Division, Quality Development Department, Chugai Pharma Manufacturing, 5-1, Ukima, 5-chome, Kita-ku, Tokyo 115-8543, Japan – sequence: 23 givenname: Hiroyuki surname: Suetomo fullname: Suetomo, Hiroyuki organization: Bio Process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd., 100-1, Hagiwara-machi, Takasaki, Gunma 370-0013, Japan – sequence: 24 givenname: Kazuhiro surname: Takegami fullname: Takegami, Kazuhiro organization: CMC Analysis Laboratory, Toray Research Center, Inc., 9-1, Oe-cho, Minato-ku, Nagoya, Aichi 455-8502, Japan – sequence: 25 givenname: Momoko surname: Takeuchi fullname: Takeuchi, Momoko organization: Pharmaceutical Research Laboratories, Nippon Kayaku Co., Ltd., 3-31-12, Shimo, Kita-ku, Tokyo 115-0042, Japan – sequence: 26 givenname: Hidehito surname: Yasukawa fullname: Yasukawa, Hidehito organization: Research Division, Formulation Development, Biomanufacturing Technology, JCR Pharmaceuticals Co., Ltd., 2-2-9 Murotani, Nishi-ku, Kobe, Hyogo 651-2241, Japan – sequence: 27 givenname: Susumu surname: Uchiyama fullname: Uchiyama, Susumu organization: Department of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan – sequence: 28 givenname: Akiko surname: Ishii-Watabe fullname: Ishii-Watabe, Akiko organization: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30121316$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU9r3DAQxUVJaTZpv0APRcdevB3JK9lbekmX_CsLKaQ5i7Et7WqxJVeyt9lP0q9bOZtceggMDAPv9wbeOyMnzjtNyEcGcwZMftnNH_ttnHNg5RzSgHxDZkxwyCSw4oTMADjPcrFYnpKzGHeQFCDEO3KaA-MsZ3JG_q5822LlAw52r-n9MDYHanygFw7bQ7SRekPvx2pvo61aTX9iGGzd6kgfonUbetX6P_S2w810oGvo2m62A72rYj1Ont59pZePvQ5WuzpR1tEf2KPTUdPv1vdbDB3Wekym2NKVd9GnB2P3nrw12Eb94Xmfk4ery1-rm2x9d327ulhn9ULKIWtMgVpUojESSy5LI7gUjDec4RIKwKaoDJbLAs2SMy4WopQckRtpgCdwkZ-Tz0ffPvjfo46D6mysdcrEaT9GxWEJOQgpWZJ-epaOVacb1QfbYTiolzCToDwK6uBjDNqo2g5PGQwBbasYqKk3tVNTb2rqTUEamFD-H_ri_ir07QjpFNDe6qBi_RRzY4OuB9V4-xr-D7XxtEw |
CitedBy_id | crossref_primary_10_1016_j_ejpb_2023_07_018 crossref_primary_10_1007_s12247_024_09810_4 crossref_primary_10_1016_j_xphs_2019_08_009 crossref_primary_10_1021_acs_molpharmaceut_3c00859 crossref_primary_10_1016_j_xphs_2020_03_024 crossref_primary_10_1016_j_xphs_2022_08_006 crossref_primary_10_1016_j_xphs_2019_10_046 crossref_primary_10_1016_j_xphs_2022_01_016 crossref_primary_10_1016_j_xphs_2022_07_006 crossref_primary_10_1016_j_xphs_2022_10_010 crossref_primary_10_1016_j_xphs_2023_10_007 crossref_primary_10_1016_j_xphs_2024_04_011 crossref_primary_10_1007_s12247_023_09734_5 crossref_primary_10_1016_j_ijbiomac_2021_07_012 crossref_primary_10_1016_j_ejpb_2021_07_001 crossref_primary_10_1016_j_ijpharm_2025_125373 crossref_primary_10_1016_j_xphs_2019_10_034 crossref_primary_10_1016_j_xphs_2021_06_002 crossref_primary_10_1016_j_xphs_2020_01_001 crossref_primary_10_1016_j_xphs_2022_03_011 crossref_primary_10_1142_S1793545822440060 crossref_primary_10_1016_j_xphs_2021_12_011 crossref_primary_10_1016_j_xphs_2020_10_044 crossref_primary_10_1016_j_xphs_2019_10_017 crossref_primary_10_1016_j_xphs_2020_01_009 crossref_primary_10_1016_j_ijbiomac_2022_06_176 crossref_primary_10_1007_s11095_022_03170_9 crossref_primary_10_1016_j_ijpharm_2024_124778 crossref_primary_10_1016_j_ijpharm_2024_124577 crossref_primary_10_1021_acs_molpharmaceut_4c00681 crossref_primary_10_1016_j_ejpb_2023_01_017 crossref_primary_10_1016_j_ijbiomac_2023_123439 crossref_primary_10_1016_j_seppur_2023_126036 crossref_primary_10_1016_j_jpba_2019_112802 crossref_primary_10_1208_s12248_019_0384_0 crossref_primary_10_1016_j_xphs_2021_09_047 crossref_primary_10_1002_amp2_10142 crossref_primary_10_1016_j_ijpharm_2020_119704 crossref_primary_10_1007_s11095_023_03474_4 crossref_primary_10_1016_j_xphs_2021_09_021 |
Cites_doi | 10.1002/jps.23786 10.1208/s12248-013-9522-2 10.1016/j.ijpharm.2012.04.040 10.1021/ja042898o 10.1007/s11095-011-0590-7 10.1016/S0022-3549(15)00180-X 10.1002/jps.22046 10.1007/s11095-015-1817-9 10.1002/jps.23242 10.1002/jps.23973 10.1001/jama.300.16.1887 10.1016/j.drudis.2014.09.003 10.1080/19420862.2018.1415671 10.1002/jps.23434 10.1002/jps.21719 10.1002/jps.22732 10.1208/s12248-010-9233-x 10.1002/jps.20237 10.1016/j.ejps.2013.12.014 10.1002/jps.23408 10.1002/jps.24184 10.1002/jps.23244 10.1074/jbc.M110.160457 10.1002/jps.21834 10.1016/j.xphs.2017.02.005 10.1002/jps.21530 10.1002/jps.23479 |
ContentType | Journal Article |
Copyright | 2019 The Authors Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2019 The Authors – notice: Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.xphs.2018.08.006 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-6017 |
EndPage | 841 |
ExternalDocumentID | 30121316 10_1016_j_xphs_2018_08_006 S0022354918305057 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OC 1ZS 31~ 36B 3O- 3WU 4.4 457 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52W 52X 53G 5GY 5RE 5VS 66C 6I. 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 A8Z AAEVG AAFTH AAKUH AALRI AAMMB AANHP AAOIN AAONW AAXUO AAYOK AAYWO AAZKR ABCQN ABEML ABFRF ABIJN ABJNI ABMAC ABOCM ABPVW ACBWZ ACGFO ACGFS ACIWK ACPRK ACRPL ACSCC ACVFH ACXQS ACYXJ ADBBV ADCNI ADIZJ ADNMO ADVLN AEFGJ AEFWE AEIMD AENEX AEUPX AFBPY AFFNX AFJKZ AFPUW AFRAH AFTJW AFZJQ AGCQF AGHFR AGQPQ AGXDD AI. AIDQK AIDYY AIGII AITUG AJAOE AKBMS AKRWK AKYEP ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMRAJ APXCP ATUGU AZBYB BAFTC BDRZF BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DU5 E3Z EBD EBS EFKBS EJD EMB EMOBN F00 F01 F04 F5P FDB FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HHY HHZ HOLLA HVGLF HX~ HZ~ IX1 J0M JPC KQQ L7B LAW LC2 LC3 LH4 LP6 LP7 LSO LW6 M41 M6Q MK0 MK4 N04 N05 N9A NF~ NNB O9- OIG P2P P2X P4D Q.N Q11 QB0 QRW R.K RNS ROL RX1 RYL SSZ SUPJJ SV3 UB1 UKR UNMZH V2E V8K VH1 W8V W99 WH7 WIB WJL WQJ WYUIH XG1 XPP XV2 Y6R ZE2 ZGI ZXP ~IA ~WT AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c466t-df7ae5b5df6a8268f526512d21a9070ad7bfa897af9212545862aa2f6f02ae543 |
ISSN | 0022-3549 1520-6017 |
IngestDate | Fri Jul 11 01:13:32 EDT 2025 Mon Jul 21 05:36:45 EDT 2025 Thu Apr 24 23:08:11 EDT 2025 Tue Jul 01 02:09:31 EDT 2025 Sun Jul 20 02:20:18 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | standards particle size microparticle(s) image analysis protein aggregation |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c466t-df7ae5b5df6a8268f526512d21a9070ad7bfa897af9212545862aa2f6f02ae543 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://dx.doi.org/10.1016/j.xphs.2018.08.006 |
PMID | 30121316 |
PQID | 2090305661 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_2090305661 pubmed_primary_30121316 crossref_citationtrail_10_1016_j_xphs_2018_08_006 crossref_primary_10_1016_j_xphs_2018_08_006 elsevier_sciencedirect_doi_10_1016_j_xphs_2018_08_006 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2019 2019-02-00 20190201 |
PublicationDateYYYYMMDD | 2019-02-01 |
PublicationDate_xml | – month: 02 year: 2019 text: February 2019 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of pharmaceutical sciences |
PublicationTitleAlternate | J Pharm Sci |
PublicationYear | 2019 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Fradkin, Carpenter, Randolph (bib19) 2009; 98 Ripple, Wayment, Carrier (bib30) 2011; 14 Gerhardt, Bonam, Bee, Carpenter, Randolph (bib11) 2013; 102 Zolls, Gregoritza, Tantipolphan (bib25) 2013; 102 Kirshner (bib21) 2012 Pedersen, Persson (bib22) 2014; 103 Rosenberg, Verthelyi, Cherney (bib7) 2012; 101 Strehl, Rombach-Riegraf, Diez (bib26) 2012; 29 Barnard, Rhyner, Carpenter (bib23) 2012; 101 Demeule, Messick, Shire, Liu (bib28) 2010; 12 Basu, Krishnan, Thirumangalathu, Randolph, Carpenter (bib10) 2013; 102 Krayukhina, Tsumoto, Uchiyama, Fukui (bib6) 2015; 104 Roach, Farrar, Perry (bib12) 2005; 127 Zolls, Weinbuch, Wiggenhorn (bib32) 2013; 15 Kaplon, Reichert (bib3) 2018; 10 Sharma, Oma, Pollo, Sukumar (bib27) 2010; 99 Ripple, Hu (bib33) 2016; 33 Carpenter, Randolph, Jiskoot (bib4) 2009; 98 Chi, Weickmann, Carpenter, Manning, Randolph (bib14) 2005; 94 (bib20) 2013 Cavicchi, Collett, Telikepalli, Hu, Carrier, Ripple (bib31) 2017; 106 Thirumangalathu, Krishnan, Ricci, Brems, Randolph, Carpenter (bib13) 2009; 98 Werk, Volkin, Mahler (bib29) 2014; 53 Wang, Singh, Li, Toler, King, Nema (bib9) 2012; 431 Giezen, Mantel-Teeuwisse, Straus, Schellekens, Leufkens, Egberts (bib1) 2008; 300 (bib16) 2014 (bib17) 2014 (bib18) 2007 Ripple, Dimitrova (bib24) 2012; 101 Kinch (bib2) 2015; 20 Gerhardt, McGraw, Schwartz, Bee, Carpenter, Randolph (bib5) 2014; 103 Kotarek, Stuart, De Paoli (bib8) 2016; 105 Joubert, Luo, Nashed-Samuel, Wypych, Narhi (bib15) 2011; 286 Krayukhina (10.1016/j.xphs.2018.08.006_bib6) 2015; 104 Gerhardt (10.1016/j.xphs.2018.08.006_bib11) 2013; 102 (10.1016/j.xphs.2018.08.006_bib16) 2014 Kaplon (10.1016/j.xphs.2018.08.006_bib3) 2018; 10 Thirumangalathu (10.1016/j.xphs.2018.08.006_bib13) 2009; 98 Giezen (10.1016/j.xphs.2018.08.006_bib1) 2008; 300 Carpenter (10.1016/j.xphs.2018.08.006_bib4) 2009; 98 Chi (10.1016/j.xphs.2018.08.006_bib14) 2005; 94 Barnard (10.1016/j.xphs.2018.08.006_bib23) 2012; 101 Wang (10.1016/j.xphs.2018.08.006_bib9) 2012; 431 Werk (10.1016/j.xphs.2018.08.006_bib29) 2014; 53 Demeule (10.1016/j.xphs.2018.08.006_bib28) 2010; 12 Ripple (10.1016/j.xphs.2018.08.006_bib30) 2011; 14 Gerhardt (10.1016/j.xphs.2018.08.006_bib5) 2014; 103 Kotarek (10.1016/j.xphs.2018.08.006_bib8) 2016; 105 Ripple (10.1016/j.xphs.2018.08.006_bib24) 2012; 101 Sharma (10.1016/j.xphs.2018.08.006_bib27) 2010; 99 Basu (10.1016/j.xphs.2018.08.006_bib10) 2013; 102 (10.1016/j.xphs.2018.08.006_bib20) 2013 Zolls (10.1016/j.xphs.2018.08.006_bib25) 2013; 102 Ripple (10.1016/j.xphs.2018.08.006_bib33) 2016; 33 (10.1016/j.xphs.2018.08.006_bib17) 2014 Fradkin (10.1016/j.xphs.2018.08.006_bib19) 2009; 98 Strehl (10.1016/j.xphs.2018.08.006_bib26) 2012; 29 Roach (10.1016/j.xphs.2018.08.006_bib12) 2005; 127 Pedersen (10.1016/j.xphs.2018.08.006_bib22) 2014; 103 (10.1016/j.xphs.2018.08.006_bib18) 2007 Zolls (10.1016/j.xphs.2018.08.006_bib32) 2013; 15 Rosenberg (10.1016/j.xphs.2018.08.006_bib7) 2012; 101 Kinch (10.1016/j.xphs.2018.08.006_bib2) 2015; 20 Kirshner (10.1016/j.xphs.2018.08.006_bib21) 2012 Cavicchi (10.1016/j.xphs.2018.08.006_bib31) 2017; 106 Joubert (10.1016/j.xphs.2018.08.006_bib15) 2011; 286 |
References_xml | – volume: 101 start-page: 140 year: 2012 end-page: 153 ident: bib23 article-title: Critical evaluation and guidance for using the coulter method for counting subvisible particles in protein solutions publication-title: J Pharm Sci – volume: 104 start-page: 527 year: 2015 end-page: 535 ident: bib6 article-title: Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins publication-title: J Pharm Sci – volume: 102 start-page: 429 year: 2013 end-page: 440 ident: bib11 article-title: Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces publication-title: J Pharm Sci – volume: 101 start-page: 3568 year: 2012 end-page: 3579 ident: bib24 article-title: Protein particles: what we know and what we do not know publication-title: J Pharm Sci – volume: 15 start-page: 1200 year: 2013 end-page: 1211 ident: bib32 article-title: Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments publication-title: AAPS J – volume: 10 start-page: 183 year: 2018 end-page: 203 ident: bib3 article-title: Antibodies to watch in 2018 publication-title: MAbs – volume: 98 start-page: 3247 year: 2009 end-page: 3264 ident: bib19 article-title: Immunogenicity of aggregates of recombinant human growth hormone in mouse models publication-title: J Pharm Sci – volume: 29 start-page: 594 year: 2012 end-page: 602 ident: bib26 article-title: Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: a novel multiparametric image filter for sub-visible particles in microflow imaging analysis publication-title: Pharm Res – volume: 53 start-page: 95 year: 2014 end-page: 108 ident: bib29 article-title: Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods publication-title: Eur J Pharm Sci – volume: 101 start-page: 3560 year: 2012 end-page: 3567 ident: bib7 article-title: Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins publication-title: J Pharm Sci – year: 2012 ident: bib21 article-title: Regulatory Expectations for Analysis of Aggregates and Particles – volume: 98 start-page: 1201 year: 2009 end-page: 1205 ident: bib4 article-title: Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality publication-title: J Pharm Sci – volume: 99 start-page: 2628 year: 2010 end-page: 2642 ident: bib27 article-title: Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging publication-title: J Pharm Sci – volume: 94 start-page: 256 year: 2005 end-page: 274 ident: bib14 article-title: Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation publication-title: J Pharm Sci – volume: 300 start-page: 1887 year: 2008 end-page: 1896 ident: bib1 article-title: Safety-related regulatory actions for biologicals approved in the United States and the European Union publication-title: JAMA – volume: 286 start-page: 25118 year: 2011 end-page: 25133 ident: bib15 article-title: Classification and characterization of therapeutic antibody aggregates publication-title: J Biol Chem – volume: 431 start-page: 1 year: 2012 end-page: 11 ident: bib9 article-title: Immunogenicity of protein aggregates--concerns and realities publication-title: Int J Pharm – year: 2013 ident: bib20 article-title: Immunogenicity Assessment for Therapeutic Protein Products (Draft Guidance) – year: 2014 ident: bib16 publication-title: USP/NF Monograph <787>. Subvisible Particulate Matter in Therapeutic Protein Injections – volume: 106 start-page: 1499 year: 2017 end-page: 1507 ident: bib31 article-title: Variable threshold method for determining the boundaries of imaged subvisible particles publication-title: J Pharm Sci – volume: 105 start-page: 1023 year: 2016 end-page: 1027 ident: bib8 article-title: Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events publication-title: J Pharm Sci – volume: 127 start-page: 8168 year: 2005 end-page: 8173 ident: bib12 article-title: Interpretation of protein adsorption: surface-induced conformational changes publication-title: J Am Chem Soc – volume: 20 start-page: 393 year: 2015 end-page: 398 ident: bib2 article-title: An overview of FDA-approved biologics medicines publication-title: Drug Discov Today – volume: 14 start-page: 90 year: 2011 end-page: 96 ident: bib30 article-title: Standards for the optical detection of protein particles publication-title: Amer Pharm Rev – year: 2007 ident: bib18 publication-title: United States Pharmacopeia and National Formulary (USP29- NF24) – volume: 102 start-page: 1434 year: 2013 end-page: 1446 ident: bib25 article-title: How subvisible particles become invisible-relevance of the refractive index for protein particle analysis publication-title: J Pharm Sci – volume: 12 start-page: 708 year: 2010 end-page: 715 ident: bib28 article-title: Characterization of particles in protein solutions: reaching the limits of current technologies publication-title: AAPS J – volume: 103 start-page: 1601 year: 2014 end-page: 1612 ident: bib5 article-title: Protein aggregation and particle formation in prefilled glass syringes publication-title: J Pharm Sci – volume: 33 start-page: 653 year: 2016 end-page: 672 ident: bib33 article-title: Correcting the relative bias of light obscuration and flow imaging particle counters publication-title: Pharm Res – year: 2014 ident: bib17 publication-title: USP/NF Monograph <788>. Particulate Matter in Injections – volume: 103 start-page: 107 year: 2014 end-page: 114 ident: bib22 article-title: Unmasking translucent protein particles by improved micro-flow imaging algorithms publication-title: J Pharm Sci – volume: 102 start-page: 852 year: 2013 end-page: 865 ident: bib10 article-title: IgG1 aggregation and particle formation induced by silicone-water interfaces on siliconized borosilicate glass beads: a model for siliconized primary containers publication-title: J Pharm Sci – volume: 98 start-page: 3167 year: 2009 end-page: 3181 ident: bib13 article-title: Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution publication-title: J Pharm Sci – volume: 103 start-page: 107 issue: 1 year: 2014 ident: 10.1016/j.xphs.2018.08.006_bib22 article-title: Unmasking translucent protein particles by improved micro-flow imaging algorithms publication-title: J Pharm Sci doi: 10.1002/jps.23786 – volume: 15 start-page: 1200 issue: 4 year: 2013 ident: 10.1016/j.xphs.2018.08.006_bib32 article-title: Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments publication-title: AAPS J doi: 10.1208/s12248-013-9522-2 – year: 2007 ident: 10.1016/j.xphs.2018.08.006_bib18 – year: 2014 ident: 10.1016/j.xphs.2018.08.006_bib16 – volume: 431 start-page: 1 issue: 1-2 year: 2012 ident: 10.1016/j.xphs.2018.08.006_bib9 article-title: Immunogenicity of protein aggregates--concerns and realities publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2012.04.040 – volume: 127 start-page: 8168 issue: 22 year: 2005 ident: 10.1016/j.xphs.2018.08.006_bib12 article-title: Interpretation of protein adsorption: surface-induced conformational changes publication-title: J Am Chem Soc doi: 10.1021/ja042898o – volume: 29 start-page: 594 issue: 2 year: 2012 ident: 10.1016/j.xphs.2018.08.006_bib26 article-title: Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: a novel multiparametric image filter for sub-visible particles in microflow imaging analysis publication-title: Pharm Res doi: 10.1007/s11095-011-0590-7 – volume: 105 start-page: 1023 issue: 3 year: 2016 ident: 10.1016/j.xphs.2018.08.006_bib8 article-title: Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events publication-title: J Pharm Sci doi: 10.1016/S0022-3549(15)00180-X – volume: 99 start-page: 2628 issue: 6 year: 2010 ident: 10.1016/j.xphs.2018.08.006_bib27 article-title: Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging publication-title: J Pharm Sci doi: 10.1002/jps.22046 – volume: 33 start-page: 653 issue: 3 year: 2016 ident: 10.1016/j.xphs.2018.08.006_bib33 article-title: Correcting the relative bias of light obscuration and flow imaging particle counters publication-title: Pharm Res doi: 10.1007/s11095-015-1817-9 – volume: 101 start-page: 3568 issue: 10 year: 2012 ident: 10.1016/j.xphs.2018.08.006_bib24 article-title: Protein particles: what we know and what we do not know publication-title: J Pharm Sci doi: 10.1002/jps.23242 – volume: 103 start-page: 1601 issue: 6 year: 2014 ident: 10.1016/j.xphs.2018.08.006_bib5 article-title: Protein aggregation and particle formation in prefilled glass syringes publication-title: J Pharm Sci doi: 10.1002/jps.23973 – year: 2014 ident: 10.1016/j.xphs.2018.08.006_bib17 – volume: 14 start-page: 90 year: 2011 ident: 10.1016/j.xphs.2018.08.006_bib30 article-title: Standards for the optical detection of protein particles publication-title: Amer Pharm Rev – volume: 300 start-page: 1887 issue: 16 year: 2008 ident: 10.1016/j.xphs.2018.08.006_bib1 article-title: Safety-related regulatory actions for biologicals approved in the United States and the European Union publication-title: JAMA doi: 10.1001/jama.300.16.1887 – volume: 20 start-page: 393 issue: 4 year: 2015 ident: 10.1016/j.xphs.2018.08.006_bib2 article-title: An overview of FDA-approved biologics medicines publication-title: Drug Discov Today doi: 10.1016/j.drudis.2014.09.003 – volume: 10 start-page: 183 issue: 2 year: 2018 ident: 10.1016/j.xphs.2018.08.006_bib3 article-title: Antibodies to watch in 2018 publication-title: MAbs doi: 10.1080/19420862.2018.1415671 – volume: 102 start-page: 852 issue: 3 year: 2013 ident: 10.1016/j.xphs.2018.08.006_bib10 article-title: IgG1 aggregation and particle formation induced by silicone-water interfaces on siliconized borosilicate glass beads: a model for siliconized primary containers publication-title: J Pharm Sci doi: 10.1002/jps.23434 – volume: 98 start-page: 3167 issue: 9 year: 2009 ident: 10.1016/j.xphs.2018.08.006_bib13 article-title: Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution publication-title: J Pharm Sci doi: 10.1002/jps.21719 – year: 2013 ident: 10.1016/j.xphs.2018.08.006_bib20 – volume: 101 start-page: 140 issue: 1 year: 2012 ident: 10.1016/j.xphs.2018.08.006_bib23 article-title: Critical evaluation and guidance for using the coulter method for counting subvisible particles in protein solutions publication-title: J Pharm Sci doi: 10.1002/jps.22732 – volume: 12 start-page: 708 issue: 4 year: 2010 ident: 10.1016/j.xphs.2018.08.006_bib28 article-title: Characterization of particles in protein solutions: reaching the limits of current technologies publication-title: AAPS J doi: 10.1208/s12248-010-9233-x – volume: 94 start-page: 256 issue: 2 year: 2005 ident: 10.1016/j.xphs.2018.08.006_bib14 article-title: Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation publication-title: J Pharm Sci doi: 10.1002/jps.20237 – volume: 53 start-page: 95 year: 2014 ident: 10.1016/j.xphs.2018.08.006_bib29 article-title: Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2013.12.014 – volume: 102 start-page: 429 issue: 2 year: 2013 ident: 10.1016/j.xphs.2018.08.006_bib11 article-title: Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces publication-title: J Pharm Sci doi: 10.1002/jps.23408 – volume: 104 start-page: 527 issue: 2 year: 2015 ident: 10.1016/j.xphs.2018.08.006_bib6 article-title: Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins publication-title: J Pharm Sci doi: 10.1002/jps.24184 – volume: 101 start-page: 3560 issue: 10 year: 2012 ident: 10.1016/j.xphs.2018.08.006_bib7 article-title: Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins publication-title: J Pharm Sci doi: 10.1002/jps.23244 – volume: 286 start-page: 25118 issue: 28 year: 2011 ident: 10.1016/j.xphs.2018.08.006_bib15 article-title: Classification and characterization of therapeutic antibody aggregates publication-title: J Biol Chem doi: 10.1074/jbc.M110.160457 – volume: 98 start-page: 3247 issue: 9 year: 2009 ident: 10.1016/j.xphs.2018.08.006_bib19 article-title: Immunogenicity of aggregates of recombinant human growth hormone in mouse models publication-title: J Pharm Sci doi: 10.1002/jps.21834 – volume: 106 start-page: 1499 issue: 6 year: 2017 ident: 10.1016/j.xphs.2018.08.006_bib31 article-title: Variable threshold method for determining the boundaries of imaged subvisible particles publication-title: J Pharm Sci doi: 10.1016/j.xphs.2017.02.005 – volume: 98 start-page: 1201 issue: 4 year: 2009 ident: 10.1016/j.xphs.2018.08.006_bib4 article-title: Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality publication-title: J Pharm Sci doi: 10.1002/jps.21530 – year: 2012 ident: 10.1016/j.xphs.2018.08.006_bib21 – volume: 102 start-page: 1434 issue: 5 year: 2013 ident: 10.1016/j.xphs.2018.08.006_bib25 article-title: How subvisible particles become invisible-relevance of the refractive index for protein particle analysis publication-title: J Pharm Sci doi: 10.1002/jps.23479 |
SSID | ssj0006055 |
Score | 2.4672651 |
Snippet | The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 832 |
SubjectTerms | image analysis Immunoglobulins, Intravenous - chemistry Japan Light microparticle(s) Optical Imaging Particle Size Protein Aggregates protein aggregation Technology, Pharmaceutical |
Title | Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium |
URI | https://dx.doi.org/10.1016/j.xphs.2018.08.006 https://www.ncbi.nlm.nih.gov/pubmed/30121316 https://www.proquest.com/docview/2090305661 |
Volume | 108 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXc9NJL0b3uhilQ5KLI0EpLvQVBDDdwEqOQAd8EyhIRZbEMW2rr_Eh_oZ_ZIaktsROkvQgGQcqC3tNwZjgLIV9o7FNmJVSfRY6jO7il6B7ntt6PbNuMTRYnpkhwPj6hw4lzNHWnnc6fVtRSkUe92fXWvJL_QRXHEFeRJfsPyNY3xQH8jfjiFRHG64MwPmhA_KFCAlX4ZbvSCEoGkT8uEqTGVRScpgIFBpfZT-3blepTJBzoI2Gpa6coSoplHfXRFEOWobNHuLuKrpWii-Xi7IZDXDT_RG0-Las7bKq8t-aXu29znJSus5VsMqwdsxXLs9r9c5ZGTKm5w3SZXWSN3Fyya9U9XNu_SJf1HhNkKLwKScYkXxVZ27kh8qnqQJFSHgvr1lDpnb1ky1glxA2vxVarJZI95T_d2CqU1-K892shy7abnizlamypy31yGg4mo1EYHE6DR-SxhQaJNN6_N4XK0Ch0ZWXe8tHK9CwVSXj7H-5Sge4ycaSqEzwjT0vAYF-x5TnpJPMXZHeswFvvQdDk7K32YBfGTfnz9Uvy-wYrQbISkJVQsRIyDg0roWYlSFaCYCWUrARkJUhWQouVX6HFSUjnUHESNjgJDSdfkcngMDgY6mX7D33mUJrrMe-zxI3cmFOGRrDHRScH04otk_m4UbG4H3Hm-X3GfdS_xAEwtRizOOWGhQsd-zXZmWfz5C0B1-Kz2OonkYH6NiqoHt6C2zxm1LZ86vldYlaIhLOyNr5o0XIZVkGQ56FAMRQohqJvq0G7RKvXLFRlmHtnuxXQYfl1KZ01RD7eu-5zxYoQBb84zcMXmhViki_tf2p2yRtFl_o5bFmp0aTvHrD6PXnSfHkfyE6-LJKPqGjn0SfJ8b9Oatxq |
linkProvider | Wiley-Blackwell |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Collaborative+Study+for+Analysis+of+Subvisible+Particles+Using+Flow+Imaging+and+Light+Obscuration%3A+Experiences+in+Japanese+Biopharmaceutical+Consortium&rft.jtitle=Journal+of+pharmaceutical+sciences&rft.au=Kiyoshi%2C+Masato&rft.au=Shibata%2C+Hiroko&rft.au=Harazono%2C+Akira&rft.au=Torisu%2C+Tetsuo&rft.date=2019-02-01&rft.issn=1520-6017&rft.eissn=1520-6017&rft.volume=108&rft.issue=2&rft.spage=832&rft_id=info:doi/10.1016%2Fj.xphs.2018.08.006&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3549&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3549&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3549&client=summon |